Ignite Creation Date:
2025-12-25 @ 2:56 AM
Ignite Modification Date:
2025-12-26 @ 1:36 AM
Study NCT ID:
NCT04365933
Status:
COMPLETED
Last Update Posted:
2022-08-25
First Post:
2020-04-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir
Sponsor:
Enyo Pharma
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-05-25
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-16
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-11-29
Completion Date Type:
ACTUAL
First Submit Date:
2020-04-23
First Submit QC Date:
None
Study First Post Date:
2020-04-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-08-22
Last Update Post Date:
2022-08-25
Last Update Post Date Type:
ACTUAL